182 related articles for article (PubMed ID: 29620932)
1. Clinical Benefits and Cost-Effectiveness of Laboratory Monitoring Strategies to Guide Antiretroviral Treatment Switching in India.
Freedberg KA; Kumarasamy N; Borre ED; Ross EL; Mayer KH; Losina E; Swaminathan S; Flanigan TP; Walensky RP
AIDS Res Hum Retroviruses; 2018 Jun; 34(6):486-497. PubMed ID: 29620932
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
[TBL] [Abstract][Full Text] [Related]
3. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies.
Ouattara EN; Robine M; Eholié SP; MacLean RL; Moh R; Losina E; Gabillard D; Paltiel AD; Danel C; Walensky RP; Anglaret X; Freedberg KA
Clin Infect Dis; 2016 Jun; 62(11):1454-1462. PubMed ID: 26936666
[TBL] [Abstract][Full Text] [Related]
4. The value of point-of-care CD4+ and laboratory viral load in tailoring antiretroviral therapy monitoring strategies to resource limitations.
Hyle EP; Jani IV; Rosettie KL; Wood R; Osher B; Resch S; Pei PP; Maggiore P; Freedberg KA; Peter T; Parker RA; Walensky RP
AIDS; 2017 Sep; 31(15):2135-2145. PubMed ID: 28906279
[TBL] [Abstract][Full Text] [Related]
5. How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa?
Scott Braithwaite R; Nucifora KA; Toohey C; Kessler J; Uhler LM; Mentor SM; Keebler D; Hallett T
AIDS; 2014 Jan; 28 Suppl 1(0 1):S73-83. PubMed ID: 24468949
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples.
Walensky RP; Ross EL; Kumarasamy N; Wood R; Noubary F; Paltiel AD; Nakamura YM; Godbole SV; Panchia R; Sanne I; Weinstein MC; Losina E; Mayer KH; Chen YQ; Wang L; McCauley M; Gamble T; Seage GR; Cohen MS; Freedberg KA
N Engl J Med; 2013 Oct; 369(18):1715-25. PubMed ID: 24171517
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact and cost-effectiveness of expanded voluntary HIV testing in India.
Venkatesh KK; Becker JE; Kumarasamy N; Nakamura YM; Mayer KH; Losina E; Swaminathan S; Flanigan TP; Walensky RP; Freedberg KA
PLoS One; 2013; 8(5):e64604. PubMed ID: 23741348
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis.
Ouattara EN; MacLean RL; Danel C; Borre ED; Gabillard D; Huang M; Moh R; Paltiel AD; Eholié SP; Walensky RP; Anglaret X; Freedberg KA
PLoS One; 2019; 14(6):e0219068. PubMed ID: 31247009
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.
Ciaranello AL; Doherty K; Penazzato M; Lindsey JC; Harrison L; Kelly K; Walensky RP; Essajee S; Losina E; Muhe L; Wools-Kaloustian K; Ayaya S; Weinstein MC; Palumbo P; Freedberg KA
AIDS; 2015 Jun; 29(10):1247-59. PubMed ID: 25870982
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study.
Sharma M; Mudimu E; Simeon K; Bershteyn A; Dorward J; Violette LR; Akullian A; Abdool Karim SS; Celum C; Garrett N; Drain PK
Lancet HIV; 2021 Apr; 8(4):e216-e224. PubMed ID: 33347810
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of monitoring strategies for antiretroviral therapy of HIV infected patients in resource-limited settings: software tool.
Estill J; Salazar-Vizcaya L; Blaser N; Egger M; Keiser O
PLoS One; 2015; 10(3):e0119299. PubMed ID: 25793531
[TBL] [Abstract][Full Text] [Related]
13. Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives?
Braithwaite RS; Nucifora KA; Yiannoutsos CT; Musick B; Kimaiyo S; Diero L; Bacon MC; Wools-Kaloustian K
J Int AIDS Soc; 2011 Jul; 14():38. PubMed ID: 21801434
[TBL] [Abstract][Full Text] [Related]
14. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.
Levison JH; Wood R; Scott CA; Ciaranello AL; Martinson NA; Rusu C; Losina E; Freedberg KA; Walensky RP
Clin Infect Dis; 2013 Feb; 56(4):587-97. PubMed ID: 23087386
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India.
Uhler LM; Kumarasamy N; Mayer KH; Saxena A; Losina E; Muniyandi M; Stoler AW; Lu Z; Walensky RP; Flanigan TP; Bender MA; Freedberg KA; Swaminathan S;
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20862279
[TBL] [Abstract][Full Text] [Related]
16. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness.
Kimmel AD; Weinstein MC; Anglaret X; Goldie SJ; Losina E; Yazdanpanah Y; Messou E; Cotich KL; Walensky RP; Freedberg KA;
J Acquir Immune Defic Syndr; 2010 Jul; 54(3):258-68. PubMed ID: 20404739
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.
Goldie SJ; Yazdanpanah Y; Losina E; Weinstein MC; Anglaret X; Walensky RP; Hsu HE; Kimmel A; Holmes C; Kaplan JE; Freedberg KA
N Engl J Med; 2006 Sep; 355(11):1141-53. PubMed ID: 16971720
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models.
Keebler D; Revill P; Braithwaite S; Phillips A; Blaser N; Borquez A; Cambiano V; Ciaranello A; Estill J; Gray R; Hill A; Keiser O; Kessler J; Menzies NA; Nucifora KA; Vizcaya LS; Walker S; Welte A; Easterbrook P; Doherty M; Hirnschall G; Hallett TB
Lancet Glob Health; 2014 Jan; 2(1):e35-43. PubMed ID: 25104633
[TBL] [Abstract][Full Text] [Related]
19. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.
Kimmel AD; Goldie SJ; Walensky RP; Losina E; Weinstein MC; Paltiel AD; Zhang H; Freedberg KA;
Antivir Ther; 2005; 10(1):41-52. PubMed ID: 15751762
[TBL] [Abstract][Full Text] [Related]
20. The clinical and economic impact of point-of-care CD4 testing in mozambique and other resource-limited settings: a cost-effectiveness analysis.
Hyle EP; Jani IV; Lehe J; Su AE; Wood R; Quevedo J; Losina E; Bassett IV; Pei PP; Paltiel AD; Resch S; Freedberg KA; Peter T; Walensky RP
PLoS Med; 2014 Sep; 11(9):e1001725. PubMed ID: 25225800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
